The WHO grading based on a comprehensive evaluation of morphology, cell biology, genetics and immunological characteristics of primary brain tumors has been widely used as it is also a good indicator of clinical outcomes. The molecular pathology of gliomas not only serves as an adjunct to histological diagnosis but may also hold the key to developing new prognostic classifications with therapeutic implications. Despite aggressive treatment, the prognosis of malignant gliomas remains dismal. Extensive research on the genetics and epigenetics of gliomas has been carried out in order to gain a better understanding of the molecular biology of tumors. Understanding the molecular factors associated with glioma is essential for the development of an effective anti glioma chemotherapy. Several studies report characteristic genetic factors, such as O6 methylguanine DNA methyltransferase MGMT , chromosome 1p19q, epidermal growth factor receptor EGFR , TP53, and isocitrate dehydrogenase IDH 1 & IDH2, and suggest their potential role in the clinical prognosis of the tumor by determining the efficacy of anti tumor chemotherapy. Reports on the major determinants of resistance to anti glioma therapy, namely the existence of MGMT, sustained angiogenesis, and the blood brain barrier, call for novel strategies to overcome these barriers if the fight against malignant glioma is to be won. The standard therapy for malignant gliomas is maximal resection followed by the Stupp regimen of radiation and temozolomide TMZ chemotherapy. TMZ, a second generation alkylating agent, has high blood brain barrier permeability but almost half of the tumors show TMZ resistance. Various clinical trials, using TMZ as the main trunk, have tried modifying TMZ administration and combining TMZ with other anti tumor agents in order to overcome the limits of the standard TMZ based anti glioma therapy. Basic research and clinical trials continue to contribute to developing novel molecular targeting agents and novel strategies to overcome the above mentioned shortcomings.
Ninety one glioblastoma patients were prospectively divided into 3 groups early, extended, and rechallenge according to the timing of disease progression during Stupp regimen adjuvant therapy. All patients received 50 mg m 2 day TMZ on a continuous 28 28d basis for a maximum of 12 months or until disease progression. The primary endpoint was 6 months PFS which was 27.3 , 7.4 , and 35.7 in the early, extended, and rechallenge groups, respectively, and the one year survival rate from the time of study entry was 27.3 , 14.8 , and 28.6 respectively. 
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